Cancer Treatment Centers of America

We're available 24/7
(800) 615-3055

Chat online with us

Chat now

Other ways to contact us

Video
chat
Have us
call you
(800) 615-3055

Have questions? Call (800) 615-3055 to speak to a cancer information specialist.
Or we can call you.

Clinical trials

Cancer Treatment Centers of America (CTCA) is committed to bringing you new and innovative investigational cancer treatment options. One way we do this is by participating in cancer research trials and studies.

For more information regarding clinical trials, please email the Clinical Trials team at clinicaltrials@ctca-hope.com or contact one of our Oncology Information Specialists at 888-841-9129. Oncology Information Specialists are available around the clock, 24 hours a day, 7 days a week, to discuss treatment options offered at CTCA.

Breast cancer

Pilot Study of Hepatic Arterial Infusion (HAI) with Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX) in Heavily Pre-treated Patients with Liver-Predominant Metastasis from Breast Cancer

Pilot Study of Hepatic Arterial Infusion (HAI) with Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX) in Heavily Pre-treated Patients with Liver-Predominant Metastasis from Breast Cancer

Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Metastatic breast cancer trial

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer.

This study is for patients with metastatic breast cancer who are positive for BRCA1 or BRCA2 mutation and have received no more than one prior treatment for metastatic disease. This study will assess the efficacy and side effects of Veliparib.

http://clinicaltrials.gov/ct2/show/NCT01506609?term=AbbVie+M12-895&rank=1

This trial is offered at the following facilities: Midwestern Regional Medical Center

A Study of Neratinib plus Capecitabine vs. lapatinib

PUMA-NER-1301: A Study of Neratinib plus Capecitabine vs. lapatinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2 directed regimens in the metastatic setting

This study will assess the effectiveness of Neratinib plus Capecitabine to the effectiveness of lapatinib plus Capecitabine in patients with HER2 positive metastatic breast cancer.

http://clinicaltrials.gov/ct2/show/NCT01808573?term=PUMA-NER-1301&rank=1

This trial is offered at the following facilities: Midwestern Regional Medical Center

Local-regional recurrent breast cancer

A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety and Efficacy of Hyperthermia and Thermodox® (Lyso-Thermosensitive Liposomal Doxirubicin) in Patients with Local-Regional Recurrent Breast Cancer

The purpose of this research study is to compare ThermoDox developed at two different manufacturers to measure if they respond the same in the body. The Sponsor will also evaluate the effects of ThermoDox in combination with therapeutic heating of the chest wall in the treatment of recurrent regional breast cancer.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Pfizer A5481023: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex) with or without PD-0332991 (Palbociclib) +/- Goserelin in women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast cancer whose Disease Progressed After Prior Endocrine Therapy

The purpose of this study is to evaluate the efficacy and safety of Palbociclib in patients with hormone receptor-positive, HER2-Negative metastatic breast cancer who have already received endocrine therapy.

http://clinicaltrials.gov/ct2/show/NCT01942135?term=Pfizer+A5481023&rank=1

http://www.paloma3.com/

This trial is offered at the following facilities: Western Regional Medical Center, Midwestern Regional Medical Center

Metronomic Capecitabine with Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

Metronomic Capecitabine with Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Colorectal cancer

Peritoneal carcinomatosis (colorectal cancer) trial

A Phase I/II Study of the Safety and Biological Activity of Intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) Administered alone and in Combination with Standard Chemotherapy in Colorectal or Ovarian Peritoneal Carcinomatosis Patients who had Previously Received Cytoreductive Surgery plus HIPEC Therapy

To assess the safety of EGEN-001 IP treatment administered alone and in combination with standard chemotherapy in patients with colorectal peritoneal carcinomatosis who have had cytoreductive surgery plus HIPEC treatment.

This trial is offered at the following facilities: Midwestern Regional Medical Center, Southwestern Regional Medical Center

Gastrointestinal cancer

Previously treated metastatic GI, kidney or lung cancers trial

Chemoimmunotherapy with 5FU followed by Interferon in Previously treated Metastatic GI, Kidney or Lung cancers

To measure progression free survival in patients who have received at least two prior systemic therapies.

This trial is offered at the following facilities: Western Regional Medical Center

General

Preparatory regimens for hematologic malignancies

Total Marrow and Lymphatic Irradiation (TMLI) in the preparatory regimens for hematologic malignancies

This study is evaluating healthy tissue sparing treatments for Radiation Conditioning of Stem Cell Transplant patients.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Parenteral nutrition trial

Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

To examine whether Omegaven, an omega-3 based lipid emulsion, can improve or prevent further deterioration of PN-induced hepatic dysfunction (“PN” is nutrition administered through an IV line).

This trial is offered at the following facilities: Midwestern Regional Medical Center

Head and neck cancer

Radiation therapy induced oral mucositis

Use of Low Level Laser Therapy (LLLT) for the Treatment of Radiation Therapy Induced Oral Mucositis

The purpose of this study is to determine the effectiveness of low energy laser therapy for patients with radiation induced oral mucositis.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Hodgkin lymphoma

A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Millennium C25003: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

This study is for treatment-naïve patients with Ann Arbor Stage III or IV Hodgkin Lymphoma. This study will assess the effectiveness of brentuximab vedotin (ADCETRISTM) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin Lymphoma (HL).

View the trial

This trial is offered at the following facilities: Midwestern Regional Medical Center

Kidney cancer

Previously treated metastatic GI, kidney or lung cancers trial

Chemoimmunotherapy with 5FU followed by Interferon in Previously treated Metastatic GI, Kidney or Lung cancers

To measure progression free survival in patients who have received at least two prior systemic therapies.

This trial is offered at the following facilities: Western Regional Medical Center

Interleukin-2 in Metastatic Kidney Cancer

Interleukin-2 in Metastatic Kidney Cancer

The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help increase tumor shrinkage.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Lung cancer

Previously treated metastatic GI, kidney or lung cancers trial

Chemoimmunotherapy with 5FU followed by Interferon in Previously treated Metastatic GI, Kidney or Lung cancers

To measure progression free survival in patients who have received at least two prior systemic therapies.

This trial is offered at the following facilities: Western Regional Medical Center

Locally advanced or metastatic non-small cell lung cancer

LUX-Lung EAP US; An open expanded access program afatinib (BIBW 2292) for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s)

To provide early access and to evaluate the safety, tolerability and efficacy of afatinib for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutation(s).

This trial is offered at the following facilities: Southwestern Regional Medical Center

Metastatic lung cancer trial

Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors.

This study is for patients who have either primary or metastatic tumors of the lung where there is airway obstruction. This single treatment session involves the infusion of ‘nanoparticles’ (AuroShell particles) that collect in tumors which are then treated with a laser that heats the tumor cells and spares healthy tissue. This study will assess the safety of this therapy, as well as the efficacy of AuroLase therapy in destroying the targeted lesion.

This trial is offered at the following facilities: Eastern Regional Medical Center

Non-small cell lung cancer with brain metastases trial

A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC).

This study is for patients who have been diagnosed with non-small cell lung cancer (NSCLC) and currently have brain metastases. This study will try to determine if the addition of veliparib to whole brain radiation therapy is more effective than whole brain radiation therapy alone.

This trial is offered at the following facilities: Eastern Regional Medical Center

Lymphoma

The effectiveness and safety of Zevalin

Spectrum SPI-ZEV-11-301: A Phase 3, Open-label, Multicenter, Randomized study of sequential Zevalin (ibritumomab tiuxetan) vs observation in patients at least 60 years of age with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP like therapy

This study will assess the effectiveness and safety of Zevalin compared with observation in patients who are in complete remission after first-line R-CHOP or R-CHOP like therapy.

http://clinicaltrials.gov/ct2/show/NCT01510184?term=spi-zev-11-301&rank=1

This trial is offered at the following facilities: Midwestern Regional Medical Center

Melanoma

Interleukin-2 in Metastatic Melanoma

Interleukin-2 in Metastatic Melanoma

The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used in this study will help to increase tumor shrinkage.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Dacarbazine and Carmustine in Metastatic Melanoma

Dacarbazine and Carmustine in Metastatic Melanoma

The purpose of this study is to determine whether dacarbazine and carmustine at the doses and schedule used in this study will help to increase tumor shrinkage.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center, Southwestern Regional Medical Center

Phase II Trial of T-cell-based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma

Trial of T-cell based Low dose Cyclophosphamide and Outpatient Intravenous Interleukin 2 in Metastatic Melanoma

The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Non-small cell lung cancer (NSCLC)

A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)

A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)

The purpose of this study is to use Immunochemotherapy +/- Hypofractionated Radiation for complete response in solid tumors

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer

Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer)

To determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

The effectiveness of BIND-014 in patients who have stage III/IV NSCLC

BIND-014-005: An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel nanoparticles For Injectable Suspension) As Second-line Therapy To Patients With Non-Small Cell Lung Cancer

This study is for patients with stage III/IV non-small cell lung cancer (NSCLC) who have received one prior platinum-containing chemotherapy regimen for advanced or metastatic NSCLC. This study will assess the effectiveness of BIND-014 in patients who have stage III/IV NSCLC.

View the trial

This trial is offered at the following facilities: Midwestern Regional Medical Center, Eastern Regional Medical Center, Southeastern Regional Medical Center, Southwestern Regional Medical Center, Western Regional Medical Center

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as Second-line Therapy to Patients with Non-small Cell Lung Cancer

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as Second-line Therapy to Patients with Non-small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of BIND-014 in patients with advanced non-small cell lung cancer (NSCLC).

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Ovarian cancer

Peritoneal cancinomatosis (ovarian cancer) trial

A Phase I/II Study of the Safety and Biological Activity of Intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) Administered alone and in Combination with Standard Chemotherapy in Colorectal or Ovarian Peritoneal Carcinomatosis Patients who had Previously Received Cytoreductive Surgery plus HIPEC Therapy

To assess the safety of EGEN-001 IP treatment administered alone and in combination with standard chemotherapy in patients with colorectal peritoneal carcinomatosis who have had cytoreductive surgery plus HIPEC treatment.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma

To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Pancreatic cancer

Resectable pancreatic cancer trial

Multi-Modality Therapy for Untreated Patients with Resectable or Marginally Resectable Pancreatic Cancer.

Patients with pancreatic cancer will be treated with a combination of surgery, intraoperative-radiation therapy (IORT), external beam radiation and chemotherapy.

This trial is offered at the following facilities: Southwestern Regional Medical Center

A phase II study evaluating bi-weekly dosing of gemcitabine plus nab-Paclitaxel in the treatment of treatment of surgically unresectable/metastatic pancreatic cancer.

A phase II study evaluating bi-weekly dosing of gemcitabine plus nab-Paclitaxel in the treatment of treatment of surgically unresectable/metastatic pancreatic cancer.

To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

View the trial

This trial is offered at the following facilities: Western Regional Medical Center

Metastatic pancreatic cancer trial

Safety and Efficacy Study of Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) for Patients with Metastatic Adenocarcinoma of the Pancreas.

This study is for patients who have been diagnosed with pancreatic cancer and have had progression of their disease after at least one type of chemotherapy regimen. This study will assess the safety and tolerability of both high-dose and low-dose IV vitamin C when administered concurrently with Gemzar.

This trial is offered at the following facilities: Eastern Regional Medical Center

Pelvic cancer

Pelvic cancer trial

Evaluation of Hyperthermia and Radiotherapy for the Treatment of Patients with Locally Advanced Tumors of the Pelvis.

To determine if applying heat in addition to radiation therapy will help shrink tumors of the pelvis.

This trial is offered at the following facilities: Southwestern Regional Medical Center, Eastern Regional Medical Center

Prostate cancer

Evaluate the effectiveness of VT-122 in patients with progressive prostate cancer

Vicus VT1-SYS-601: A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propanolol in Patients with Clinically Progressive Prostate Cancer

This study will evaluate the effectiveness of VT-122 (study drug) to the effectiveness of physician’s choice of appropriate standard therapy in patients with clinically progressive prostate cancer.

View the trial

This trial is offered at the following facilities: Midwestern Regional Medical Center

Sarcoma, soft tissue

Metastatic liposarcoma or leiomyosarcoma trial

A Randomized Controlled Study of YONDELIS(R)(Trabectedin) or Dacarbazine for the treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide.

This is a randomized, open label multicenter study comparing the safety and efficacy of Yondelis(R) (Trabectedin) with dacarbazine among adults with unresectable, locally advanced or metastatic liposarcoma or leiomyosarcoma who were previously treated with an anthracycline and ifosfamide. Eligible patients will be randomly assigned to either the Yondelis(R) or dacarbazine treatment groups.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Metastatic soft tissue sarcoma trial

A Multicenter, Open-Label Single Arm Study of Yondelis(R)(Trabectedin)for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Excluding Leiomyosarcoma and Liposarcoma Who Have Relapse or Are Refractory to Standard of Care.

Patients who qualify for this clinical trial will receive Yondelis(R)(Trabectedin). The study will measure the safety and how well the medication is tolerated.

This trial is offered at the following facilities: Southwestern Regional Medical Center

Your browser (Internet Explorer 7) is out of date. Learn how to update your browser.